Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2012

View Archived Issues

Otsuka Pharmaceutical reports new candidate cancer therapies

Novel inhibitors of diacylglycerol O-acyltransferase 1 presented

Abbott designs novel focal adhesion kinase 1 inhibitors

AstraZeneca scientists discover novel plasminogen inhibitors

New sodium channel antagonists described

Hepatitis C vaccine shows promise in proof-of-concept trial

BRISK PS trial compares brivanib to placebo in liver cancer

Phase II data presented on ACE-031 in boys with Duchenne's muscular dystrophy

Doxapram enantiomer retains respiratory stimulant properties without adverse effects

Novel multikinase inhibitor is active in FLT3-dependent leukemia cells

Isis begins phase II ISIS-APOCIIIRx study

Genfit reports on GFT-505 study in NAFLD/NASH

Gentium receives day 180 list from EMA for defibrotide MAA

Sato Pharmaceutical set to launch anesthetic cream in Japan

FDA approves expanded dose range for schizophrenia drug

Pfizer stops phase III study of Lyrica

Phase III study of hydroxychloroquine begins in Japan

Abbott to acquire melanocortin receptor agonist

MediGene receives final milestone payment for Eligard

Pfizer offers overview of first quarter 2012

Exelixis expands cabozantinib development program

Oncolytics Biotech enters into agreement for phase II Reolysin study

NIH launches program providing researchers access to industry compounds

Phase IIIb trial of Lyrica does not meet primary endpoint

Roche terminates development of antidyslipidemia drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...